🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Zoldonrasib (mutant selective covalent inhibitor targeting the ‘ON’ state of RAS G12D. Most patients were PDAC but included NSCLC. #AACR25 KRASKickers AACR #lcsm

🚨 BREAKING at #AACR25: Big news for #HER2-mutant #NSCLC! 💥 Trastuzumab rezetecan shows: 🔹 ORR 74.5% 🔹 Median PFS 11.5 mo 🔹 88% alive at 1 year 🌟 Responses seen across HER2 mutations, even with brain mets! ✅ Manageable safety profile. 🛫 Phase 3 trial already underway!

Dr. Solange Peters presents SKYSCRAPER-01: tiragolumab + atezolizumab vs. atezo + placebo in 1L PD-L1 high advanced NSCLC As we had seen on prior press-release there is no statistically significant benefit in PFS or OS of adding anti-TIGIT to atezo #LCSM #AACR25

D3S-001 Shakes Up the KRAS G12C Landscape! "See the full KRAS G12C comparison chart ⬇️ and decide who's leading the race!" OncoAlert Oncology Brothers LARVOL OncLive.com AACR nature Yakup Ergün KOL Pulse AI #KRAS Stephen V Liu, MD Tanios Bekaii-Saab, MD Sandip Patel MD FASCO Razelle Kurzrock, MD

RAS Inhibition: Response & Resistance 🟡Primary (10–20%): KEAP1, PI3K, TP53, SMARCA4 mutations. 🟠Acquired (~60%): KRAS muts (25–30%), RTKs (20–25%), PI3K (10–15%), MYC, EMT & MAPK pathway. 🔜Rational combos and next-gen RAS inhibitors are key aacrjournals.org/cancerdiscover…

📙Gastric cancer Seminar The Lancet ✅From epidemiology to novel targets 👉thelancet.com/journals/lance… OncoAlert #cancer #gastric #oncology #MedX

NCCN 2025 Gastric Cancer Guidelines are out! HER2, PD-L1, CLDN18.2, MSI/MMR testing standard for advanced disease. Immunotherapy combinations for HER2+, PD-L1+, MSI-H, and CLDN18.2+ tumors are emphasized. The new algorithm includes CRC and HIPEC in selected patients. OncoAlert

🧠 Molecular Testing for the WHO Classification of CNS Tumors. Molecular testing is now essential for accurate CNS tumor diagnosis. Yet access remains uneven due to payer reluctance. Routine profiling improves diagnosis, prognosis & treatment. JAMA Oncology 👉🏻 DOI:

1/3🧵 🔥Hot off the press. ⭐️My co-authors & I are excited to share this just published paper ASCO #ASCO25 #ASCOEdBook on a topic that is near & dear to my heart: ✅“The ART of #Oncology #Education & #Knowledge Sharing. It is All About the “#How” 👇🏻 ascopubs.org/doi/10.1200/ED…

Phase II: Lazertinib in uncommon EGFR-mutant NSCLC ✅ ORR: 50% ✅ DCR: 89% ✅ mPFS: 10.8 mo 🧠 iORR in brain mets: 40% 🎯 Best in G719X (ORR 61%, mPFS 20.3 mo) #LungCancer #EGFR #TargetedTherapy jto.org/article/S1556-…

Our IASLC Academy is meeting today training the future leaders of #lungcancer with Rami Manochakian MD, FASCO Cancer Education Christian Rolfo Marina Garassino Triparna Sen (Sen-Lab) Pranshu Mohindra Dr. Amy C. Moore Balazs Halmos Dr. Amy C. Moore Laura Alder, MD Pilar Garrido Zosia Piotrowska Ivy Riano, M.D. Alona Zer Tony

🚨 ASCO guideline update on mCRPC. ✅PARPi + ARPI for BRCA1/2-altered, ARPI-naïve patients. ✅Olaparib post-ARPI. ✅¹⁷⁷Lu-PSMA-617, docetaxel, cabazitaxel, sipuleucel-T & radium-223 show OS benefit. ✅Early genetic testing & palliative care recommended. Journal of Clinical Oncology DOI 👉